A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers.

Trial Profile

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; CPI 444 (Primary)
  • Indications Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Corvus Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2017 According to a Corvus Pharmaceuticals media release, more than 225 patients have been enrolled. To date, RCC (single agent and combination) and NSCLC (single agent and combination) cohorts have met the protocol-defined criteria for expansion from 14 to 26 patients. For both the RCC single agent and combination cohorts, criteria for expansion to 48 patients per cohort have been reached.
    • 11 Nov 2017 Updated clinical data from the renal cell carcinoma (RCC) expansion cohorts of this study presented in a Corvus Pharmaceuticals Media Release.
    • 11 Nov 2017 According to a Corvus Pharmaceuticals media release, clinical and biomarker data were presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top